QDIS Blog

I came across this article recently and having worked for BMS years ago, I always find it interesting to see what the company is up to.

For Bristol, steady course may be best navigation

In the past I’ve not been very hot on some of the deal makings of BMS and I still have my doubts but converting into a biopharma is fraught with challenges.

In “The Development Factory: Unlocking the Potential of Process Innovation” (Gary P. Pisano) he talks about the pharmaceutical industry as one that” learns before doing”. By that he means that we can do some experiments in the lab and then somewhat reliably scale those up to large scale with some probability of success.

The biopharmaceutical industry on the other hands “learns by doing”. That is, the knowledge in how to scale these processes is not there and many things can go wrong when you change scale. Therefore you almost invariably have to run large scale experiments to figure out what parameters to control to give you the product you desire. This is one of the reasons that biopharmaceutical products are so much more expensive then your normal pill, tablet or capsule.

My point in bringing this up is it is hard to take a certain mindset and approach to development that has been instilled at BMS for a long time, and change that mentality i a short period of time and be successful at it. While they may have a chance, there still are no examples of big pharma becoming biopharma. There are examples of biopharma becoming big pharma or at least very big pharma-like (think Amgen and Genentech).

ландшафт

While I wish BMS the best (I still own a few shares of their stock as well as Genentech mentioned in this article) I don’t look for them to pull it off anytime soon and definitely not soon enough to become attractive prey for another big pharma.

Technorati Tags: BMS, Bristol-Myers Squibb, biopharma

Email Ed Vawter

Bookmark it with: | del.icio.us | Digg it | Furl | Simpy | Spurl | My Yahoo! |

After being away for sometime for a variety of reasons including a pinched nerve in my neck, I’m finally back and hoping to post to this blog several times a week, although I doubt I will be able to get back to posting daily due to work and other issues.

I did find the following article I found recently interesting as it talks about differences in Congress regarding biogenerics.

AMNews: Aug. 11, 2008. Disagreements slow progress on biogenerics legislation … American Medical News:

I think the point about the period of exclusivity is a valid point and where I think the the greatest debate will occur. While it may take a while to get compromise I think something will indeed happen on this front in the next year. It may not be a great bill but at least it will be something
Google: biogenerics or biosimilar
Yahoo: biogenerics or biosimilar
Google Scholar: biogenerics or biosimilar

Google Blogs: biogenerics or biosimilar
IceRocket Blogs: biogenerics or biosimilar
Technorati Tags: biogenerics, biosimilars

Email Ed Vawter

Bookmark it with: | del.icio.us | Digg it | Furl | Simpy | Spurl | My Yahoo! |

Wow! I read today that the EU performed raids on almost all the major drug companies on Wednesday. This includes Pfizer, Sanofi-Aventis, GlaxoSmithhKline, Astrazeneca, Merck, and Johnson & Johnson.

E.U. raids drug companies in broad inquiry

The authorities are looking for evidence of abuse of patents and illegal deals to keep cheaper generics off the market. Here is a quote form the article.

The raids will help establish if companies created barriers to competitors, whether they misused patent rights or engaged in “vexatious litigation” and if some firms abused their dominance of the market.

It will be interesting to see what comes of this if anything. I’ll but we don’t hear anything else about this for months but I’ll certainly be keeping my eyes open for further information.
Technorati Tags: GlaxoSmithKline, Johnson & Johnson, Merck, Pfizer, Sanofi-Aventis
meilleurs casino en lignejeu roulette russebaccarat frjeu slots casino en lignebonus de casino en lignepaysafecard casino bonuswww casino de pariscasino machine a sous gratuitsla règle jeu roulettewww casino gratuitesjeu la rouletteslots onlinecasino partouchewww geant casinovideo poker gratuitesjeu casino virtueljeux de casino gratuitescasino en eurojeu de hasardjeux casino poker gratuitescasino games pro 2007casino bonus 100casino en ligne frliste jeux casinomeilleurs jeux de casinojeux casino enfantle casinogéant casinos en lignefurniture Bulgariapoker les reglespoker en ligne francaisgagner poker onlinele meilleur poker en ligneworld championship pokertelecharger party pokerjouez au poker en lignetexas holdem en ligne gratuitespoker 3dpoker en ligne debutantкомпютриapprendre jouer au pokerjeux poker a telechargerjouer poker virtuelpoker hold hem gratuitesjouer au pokerjeu online poker tourtelecharger de pokerlogiciel pokerjeux video.compoker le jeujeux de poker en lignejouer au poker gratuitement

Email Ed Vawter

Bookmark it with: | del.icio.us | Digg it | Furl | Simpy | Spurl | My Yahoo! |

I Tivo’ed Frontline’s “The Medicated Child” recently and finally got around to watching it the other night. This is a follow up from an episode they did on this back in 2001. You can watch and read about it online. It was somewhat disturbing at parts especially when they mentioned a young child who was on several atypical anti-psychotics at the age of four! Here are some of the interesting points brought up:

1. There has been a 4,000% increase in diagnosis of psychiatric problems in young children over the last ten years

2. Although doctors do not agree about bipolar in young children many kids are being diagnosed as being bipolar at ages as young as four years old.

3. There is a growing number of strip mall places offering “brain scans” looking at blood flow to the brain to give a diagnosis. The company featured was co-founded by a social worker and she was the one featured giving the family the diagnosis of the problem. To me this edges on the verge of giving medical advice but not being a medical doctor.

4. In one case they highlighted it was teachers who told the parents their child had ADHD. I know teachers and I do not envy their job but I think suggesting an actual diagnosis is inappropriate.

5. Another big problem mentioned only in passing on the program was that many of these children are being treated by family pediatricians and not by child psychiatrists.

I’m not always a fan of highlighting individual cases which may or may not be typical. However, these do pull on our heart strings and it does highlight how desperate these families become when dealing with “the problem child”. I truly feel for these parents who are trying everything to help their child but nothing seems to work. Just take a look at the discussion page and read what some of these folks have gone through. This situation is what leads to some of these snake oil salesmen mentioned in point 3 above.

Part of the problem is the whole quick fix attitude especially in the US and the resulting expectation (re-inforced by the pharmaceutical industry) that a few pills can solve all your problems. I have always believed that in the case of mental issues that medication and therapy together are much more beneficial than drugs along.

I really liked the program and highly recommend it. You can watch it for free online and they also have lot of information and further interviews with experts here. There is also a Parents Guide.

I personally look forward to the day when we can run a blood test or do a brain scan and come up with a definitive diagnosis and be able to confidently prescribe medications that will solve the problem >90% of the time. Unfortunately, I don’t know if this will occur in my lifetime. This is one situation where I truly hope I am wrong.

Technorati Tags: medicated child

Email Ed Vawter

Bookmark it with: | del.icio.us | Digg it | Furl | Simpy | Spurl | My Yahoo! |

The subject of pharma spending on R&D versus Marketing is one that comes up frequently. Recently FierceBiotech has had an article on this.

Drug industry spends nearly twice as much on marketing than on research and development - FierceBiotech - Biotechnology Articles, Biotech Industry News, FDA Approval News:

Here is the link to the PLoS Medicine journal they refer to.

PLoS Medicine - The Cost of Pushing Pills: A New Estimate of Pharmaceutical Promotion Expenditures in the United States

It makes for some interesting reading. I personally think that there tends to be a discussion more on what should or should not be included as “marketing expenses” and the big picture tends to get overlooked. Maybe this is the tactic that is being used to avoid talking about the real issue.

The article does a good job I feel of at least explaining how they came up with their numbers. I’m sure there will be debate on what they decided to include and some of their assumptions but the very fact that it confirms the suspicions of the public will mean it will be readily accepted.

Their figure is $57.5 billion spent on promotion or 24.4% of every dollar versus $31.5 billion for R&D or 13.4%. THis means there is almost twice as much (1.8 actually) spent on promotion over R&D.

Here is the conclusion from that article.

From this new estimate, it appears that pharmaceutical companies spend almost twice as much on promotion as they do on R&D. These numbers clearly show how promotion predominates over R&D in the pharmaceutical industry, contrary to the industry’s claim. While the amount spent on promotion is not in itself a confirmation of Kefauver’s depiction of the pharmaceutical industry, it confirms the public image of a marketing-driven industry and provides an important argument to petition in favor of transforming the workings of the industry in the direction of more research and less promotion.

The article make the point that according to their figures the industry spends twice as much on promotion as it does on R&D. This will be controversial since it is counter to the common claim made by the pharmaceutical industry and confirms some of the perceptions of the man on the street.

I personally feel and have stated here several times that the industry as a whole does not seem to take seriously the perceptions on the street and the industry’s very actions taken to counter some of these perceptions only serves to reinforce some of those negative images out there. The industry seems to forget that perception matters and can be very damaging.

Technorati Tags: drug cost, drug marketing

Email Ed Vawter

Bookmark it with: | del.icio.us | Digg it | Furl | Simpy | Spurl | My Yahoo! |

This is the kind of stuff that gives the pharma industry a bad name. I’ve long had a problem with some of those on the marketing side who see

Congress questions Jarvik’s Lipitor lip service, credentials as part of celebrity-pitch probe - International
Herald Tribune:

I think the pharma industry needs to think about the “ethical” part of the name ethical pharmaceuticals, a term that isn’t used much anymore (maybe for good reason). I personally feel too many large pharma marketing departments are run by “soap and toothpaste” marketers who don’t understand (or don’t want to understand) the impact of what they are putting out there in terms of advertisements.

I feel there is too much emphasis on stretching the envelope of what is permissible and try to see what they can get away with and not enough focus on the perception of the drug industry in the eyes of the person on the street.

Email Ed Vawter

Bookmark it with: | del.icio.us | Digg it | Furl | Simpy | Spurl | My Yahoo! |

Here is the first of what I am sure will be plenty of approvable letter from the FDA this year. Pfizer received an approvable letter for dalbavancin, a once weekly two dose antibiotic useful for methicillin resistant bacteria. Note that this drug came to Pfizer by way of their acquisition of Vicuron.

PharmaLive: Pfizer Receives Approvable Letter from FDA for Dalbavancin :

Basically the FDA wants more evidence regarding non-inferiority as the basis for approval.

I personally think that antibiotics is NOT an area where the FDA needs to be seen as holding things up. With the rising number of MRSA infections occurring even outside the hospital the need for new antibiotics is growing and will continue to grow. Having been affected by this personally and knowing that only vancamycin worked in that case the need for new antibiotics will continue to be of concern.

Technorati Tags: dalbavancin, FDA, Pfizer

Email Ed Vawter

Bookmark it with: | del.icio.us | Digg it | Furl | Simpy | Spurl | My Yahoo! |

Here are a few of the important articles from the last couple of weeks.

Glaxo set to axe staff as crisis hits drug - Telegraph
Generic Biotech Drugs Won’t Be in U.S. Legislation Bloomberg.com: News
The Scientist : New patent rules hurt biotech?
Chemical & Engineering News: Government & Policy - Patent Reform Inches Ahead
AstraZeneca to outsource manufacturing - Times Online
AstraZeneca To Outsource Drug Manufacturing - Contract Pharma
StockHouse.com : Encysive Pharmaceuticals Receives Written Response From FDA On
Cephalon warns over pain drug deaths| Reuters
PharmaLive: Adverse Drug Events Reported to FDA Appear to Have Increased Markedly
Sanofi-Aventis Developing New Drugs: Financial News - Yahoo!
Finance
House Passes Bill to Improve Drug Safety: Financial News - Yahoo!
Finance
Senate OKs FDA drug safety bill - washingtonpost.com
Many drugs slip through regulatory ‘black hole’ - CNN.com
Bristol-Myers to buy partner Adnexus for $430 million”>SignOnSanDiego.com >
Warning issued on Cephalon painkiller | Philadelphia Inquirer | 09/27/2007

My overall observations is that there are many factors influencing the pharma industry today and these are not likely to less anytime in the near future. It would be nice to see more positive articles but those seem to be hard to come by in the current environment.

Technorati Tags: Adnexus, AstraZeneca, Bristol-Myers Squibb, Cephalon, Encysive, FDA, Glaxo, GlaxoSmithKline, Sanofi-Aventis

Email Ed Vawter

Bookmark it with: | del.icio.us | Digg it | Furl | Simpy | Spurl | My Yahoo! |

Looks like PDL Biophrma after going through some tough times and laying-off people is finally up for sale. Here are just some of the articles recently.

PDL to lay off 250, sell four drugs, shift focus - San Francisco Business Times
PDL BioPharma up for sale - Examiner.com
San Jose Mercury News - PDL for sale; CEO quits
San Jose Mercury News - PDL BioPharma’s investors urge company’s sale, executive ousters

This is case from my perspective of poor management which went on for quite a while until finally the major investors forced the ouster of the top two officers. Now it seems that the company’s only real option is to put themselves up for sale.

This will be interesting to watch and I’m not sure how it will shake out. The latest rumors are that Roche may be interested in PDL, but they have refused to comment.

Roche declines comment on PDL BioPharma deal rumours, analysts see …

Other Resources

News
Yahoo! News Search Results for pdl biopharma
pdl biopharma - Google News

Blogs
Google Blog Search: pdl biopharma
Clusty Blogs » pdl biopharma
pdl - IceRocket Blog Search
pdl biopharma: Blogs, Photos, Videos and more on Technorati

Technorati Tags: PDL Biopharma

Email Ed Vawter

Bookmark it with: | del.icio.us | Digg it | Furl | Simpy | Spurl | My Yahoo! |

Forbes recently had an article on fighting the FDA.

You Can’t Fight The FDA - Forbes.com

I have been watching this drama play out for sometime now and for me it is like watching a train wreck. You know what’s going to happen, you know it isn’t going to be pretty but there’s nothing you can do to stop it from happening. I’m not sure I understand Encysive’s rational for going through this dispute resolution process as it seemed doomed from the start.

Eye on FDA mentioned this in the Weekly Roundup - 9-7-07 and had a great article on this situation earlier: Eye on FDA: What’s at Stake with Formal Dispute Resolution

Other recent articles on this.

Encysive Pharmaceuticals Investor Relations
FDA: Encysive Drug Not Effective Enough - Forbes.com
PharmaLive: Encysive Pharmaceuticals Receives Written Response From FDA On Its Request for Formal Dispute Resolution for Thelin (Sitaxsentan Sodium)

Other Sources

fda encysive - Yahoo! Search Results
fda encysive - Google Search
Live Search: fda encysive
Clusty Search » fda encysive

Clusty Blogs » fda encysive
fda encysive - Google Blog Search

Technorati Tags: Encysive, Thelin

Email Ed Vawter

Bookmark it with: | del.icio.us | Digg it | Furl | Simpy | Spurl | My Yahoo! |